Live
Endpoints NewsFDA search for new CBER head focused on small group of final candidatesFierceBiotech‘A concerted industry-government effort’: Strand Therapeutics CEO Jake Becraft on FDA’s IND reform and ChinaBioPharma DiveCelcuity strengthens case for ASCO-spotlighted breast cancer drugEndpoints NewsSupreme Court restores mifepristone access by mailClinical OMICsBiomarker of Epigenetic Aging Could Signal DepressionAmgenPfizer vs. Amgen: Which Big Pharma Stock Is the Better Value Right Now? - TIKR.comFierceBiotechMirum maps FDA path after anti-itch candidate scores ph. 2 winSamsung BiologicsCDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike - Fierce PharmaNovartisAfter March cuts, Novartis trims another 60 roles at US headquarters - Fierce PharmaFierceBiotechTakeda pivotal trial win improves convenience for PID patients relative to HyQviaBioWorldUCB onboards more autoimmune TCEs with $2.2B Candid buyBioWorldBiggest gainers and losers for April 27-May 1, 2026
Thermo Fisher Jan 23, 2026

Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? - Zacks Investment Research

Can Specialty Diagnostics Strength Drive Thermo Fisher's Q4 Earnings? - Zacks Investment Research

Original
Body unavailable. Use the original source.